Holen Sie sich die Stockscreener-App
104.16
1.37%
1.4915
Schlusskurs vom Vortag:
$102.67
Offen:
$103.45
24-Stunden-Volumen:
44,157
Relative Volume:
0.07
Marktkapitalisierung:
$8.08B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-224.29M
KGV:
-26.71
EPS:
-3.9
Netto-Cashflow:
$-185.06M
1W Leistung:
+3.21%
1M Leistung:
-0.96%
6M Leistung:
+27.71%
1J Leistung:
+33.01%
1-Tages-Spanne:
$103.43
$105.52
1-Wochen-Bereich:
$95.50
$108.46
52-Wochen-Spanne:
$55.53
$112.88
Nuvalent Inc Stock (NUVL) Company Profile
Firmenname
Nuvalent Inc
Sektor
Branche
Telefon
508-446-2272
Adresse
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Vergleichen Sie NUVL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
104.09 | 7.97B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.00 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
810.42 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
408.64 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
812.45 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.41 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-11-12 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-10-16 | Fortgesetzt | Stifel | Buy |
| 2025-10-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-09-03 | Eingeleitet | Raymond James | Outperform |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-03-14 | Hochstufung | UBS | Neutral → Buy |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-24 | Eingeleitet | UBS | Neutral |
| 2024-08-29 | Eingeleitet | Barclays | Overweight |
| 2024-04-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-01 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | Fortgesetzt | Guggenheim | Buy |
| 2024-02-23 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-27 | Eingeleitet | Stifel | Buy |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-24 | Eingeleitet | Guggenheim | Buy |
| 2023-01-18 | Eingeleitet | Wedbush | Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
Alle ansehen
Nuvalent Inc Aktie (NUVL) Neueste Nachrichten
Will Nuvalent Inc. stock outperform tech sector in 2025Trend Reversal & Capital Efficient Trade Techniques - ulpravda.ru
How Nuvalent Inc. stock performs in weak economy2025 AllTime Highs & Low Risk Entry Point Guides - ulpravda.ru
Aug Intraday: Will Nuvalent Inc. stock outperform growth indexesJuly 2025 Chart Watch & Fast Entry High Yield Tips - ulpravda.ru
Will Nuvalent Inc. stock return to pre crisis levelsJuly 2025 Snapshot & Real-Time Volume Trigger Notifications - ulpravda.ru
How buybacks impact Nuvalent Inc. stock valueRate Hike & Community Trade Idea Sharing Platform - ulpravda.ru
Is Nuvalent Inc. stock in correction or buying zone2025 Short Interest & AI Based Buy and Sell Signals - ulpravda.ru
Is Nuvalent Inc. stock a defensive play in 2025Dividend Hike & Daily Growth Stock Investment Tips - ulpravda.ru
Nuvalent CSO Pelish sells shares worth $501,752 By Investing.com - Investing.com South Africa
Will Nuvalent’s Momentum Continue? - StocksToTrade
Nuvalent CSO Pelish sells shares worth $501,752 - Investing.com India
Nuvalent (NUVL) chief legal officer Miller sells $676k in stock - Investing.com Australia
Nuvalent (NUVL) chief development officer sells $721k in stock By Investing.com - Investing.com UK
Nuvalent (NUVL) chief development officer sells $721k in stock - Investing.com
Nuvalent initiated with a Buy at Canaccord - MSN
Aug Spikes: Will Nuvalent Inc stock outperform tech sector in 2025July 2025 Drop Watch & Expert Curated Trade Ideas - moha.gov.vn
Nuvalent's Chief Legal Officer Sells 10,000 Shares - TradingView — Track All Markets
Nuvalent, Inc. Reports Q3 2025 Progress and Financials - MSN
Avoiding Lag: Real-Time Signals in (NUVL) Movement - Stock Traders Daily
Bear Alert: How Nuvalent Inc stock performs in weak economyWeekly Stock Analysis & Daily Profit Maximizing Tips - moha.gov.vn
Nuvalent, Inc. (NASDAQ:NUVL) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Nuvalent Earnings Notes - Trefis
What's Going On With Royalty Pharma Stock Wednesday? - Benzinga
PRN_FinancialWrapper | PR NewswireNuvalent, Inc.Class A Common Stock (Nasdaq:NUVL) Stock Quote - FinancialContent
Towards 2026, Focusing on Three High-Potential Biotechnology Companies - NAI500
Nuvalent’s royalty interest acquired by Royalty Pharma - MSN
3 Biotech Stocks With Major 2026 Catalysts - Nasdaq
Truist Securities Initiates Coverage of Nuvalent (NUVL) with Buy Recommendation - MSN
Nuvalent (NUVL): Assessing an Expensive-Looking Valuation After a Strong Multi-Year Share Price Run - Yahoo Finance
Nuvalent, Inc. $NUVL Shares Bought by Voya Investment Management LLC - MarketBeat
Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference - Sahm
Nuvalent files for mixed shelf offering size not disclosedSEC filing - marketscreener.com
Technical Reactions to NUVL Trends in Macro Strategies - Stock Traders Daily
What drives Nuvalent Inc stock priceStock Buyback Updates & Follow Top Performers in the Community - earlytimes.in
Why Nuvalent Inc. stock remains a top recommendationJuly 2025 WrapUp & High Accuracy Swing Trade Signals - Улправда
Can Nuvalent Inc. stock reach $100 price target2025 Big Picture & Proven Capital Preservation Methods - Улправда
JPMorgan Chase & Co. Lowers Nuvalent (NASDAQ:NUVL) Price Target to $145.00 - MarketBeat
Aug Sentiment: Is Nuvalent Inc. stock a defensive play in 2025Weekly Loss Report & Community Trade Idea Sharing Platform - DonanımHaber
JP Morgan Lowers Target Price for Nuvalent (NUVL) to $145 | NUVL Stock News - GuruFocus
Certain Restricted Stock Units of Nuvalent, Inc. are subject to a Lock-Up Agreement Ending on 19-DEC-2025. - marketscreener.com
Certain Options of Nuvalent, Inc. are subject to a Lock-Up Agreement Ending on 19-DEC-2025. - marketscreener.com
66,836,884 Common Stock of Nuvalent, Inc. are subject to a Lock-Up Agreement Ending on 19-DEC-2025. - marketscreener.com
Analysts Are Bullish on Top Healthcare Stocks: Nuvalent (NUVL), Novan (NOVN) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Novan (NOVN) - The Globe and Mail
Barclays Reaffirms Their Buy Rating on Nuvalent (NUVL) - The Globe and Mail
UBS reiterates Buy rating on Nuvalent stock, citing Royalty Pharma deal - Investing.com Canada
[8-K] Nuvalent, Inc. Reports Material Event | NUVL SEC FilingForm 8-K - Stock Titan
Nuvalent’s Royalty Interest Acquired by Royalty Pharma - The Globe and Mail
Nuvalent Acknowledges Royalty Pharma's Acquisition of Royalty Interest - TradingView — Track All Markets
Royalty Pharma Acquires Royalty Interest in Nuvalent's Potential Lung Cancer Therapies - marketscreener.com
Royalty Pharma acquires royalty interest in Nuvalent's neladalkib and zidesamtinib for up to $315 million - marketscreener.com
Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million - Quiver Quantitative
Finanzdaten der Nuvalent Inc-Aktie (NUVL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Nuvalent Inc-Aktie (NUVL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Pelish Henry E. | Chief Scientific Officer |
Jan 05 '26 |
Sale |
97.32 |
2,496 |
242,905 |
68,552 |
| Noci Darlene | Chief Development Officer |
Jan 05 '26 |
Sale |
97.32 |
4,236 |
412,239 |
43,798 |
| Noci Darlene | Chief Development Officer |
Jan 06 '26 |
Sale |
97.16 |
3,181 |
309,081 |
40,617 |
| Miller Deborah Ann | Chief Legal Officer |
Jan 05 '26 |
Sale |
97.32 |
4,363 |
424,598 |
44,723 |
| Miller Deborah Ann | Chief Legal Officer |
Jan 06 '26 |
Sale |
97.16 |
2,589 |
251,560 |
42,134 |
| Turner Christopher Durant | Chief Medical Officer |
Jan 05 '26 |
Sale |
97.32 |
4,236 |
412,239 |
58,311 |
| Turner Christopher Durant | Chief Medical Officer |
Jan 06 '26 |
Sale |
97.16 |
3,181 |
309,081 |
55,130 |
| Balcom Alexandra | Chief Financial Officer |
Jan 05 '26 |
Sale |
97.32 |
4,236 |
412,239 |
84,914 |
| Balcom Alexandra | Chief Financial Officer |
Jan 06 '26 |
Sale |
97.16 |
3,181 |
309,081 |
81,733 |
| Porter James Richard | President and CEO |
Jan 05 '26 |
Sale |
97.32 |
17,890 |
1,741,016 |
288,172 |
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):